A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
This is a single term, open label, single Center, Phase II Trial. The study is to explore the efficacy and safety of FOLFOX-HAIC combined with Lenvatinib and Envolizumab in the treatment of patients with potentially resectable HCC.
Eligibility criteria
Qualifiers
Patients who have signed ICF and are able to perform follow-up visits and relevant procedures required in the protocol;
Age ≥ 18 years (at the time of signing the ICF);
Clinically, histologically or pathologically confirmed hepatocellular carcinoma without extrahepatic metastases;
No previous treatment containing PD- (L) 1 inhibitor and Lenvatinib;
Disqualifiers
Participate in other interventional clinical studies;
Previous or concurrent other malignancies;
History of liver transplantation or undergo liver transplantation;
History of hypersensitivity to macromolecular protein preparations, the study drug or any of the excipients;
Trial design
Treatments tested in this trial
- FOLFOX-HAIC+Lenvatinib+Envolizumab
Treatment groups
48 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov